KKR Acquires Integer in a $5.7 Bn Deal

KKR Acquires Integer Holdings in $5.7 Bn All-Cash Deal

KKR Acquires Integer Holdings in $5.7 Bn All-Cash Deal

The acquisition aims to leverage KKR’s resources to support Integer’s growth strategy, expanding its technological capabilities and strengthening its position in the global medical device industry.

Private equity firm KKR has completed the acquisition of global medical device outsourcing company Integer Holdings in an enterprise-level transaction valued at approximately $5.7 billion.

Under the terms of the agreement, Integer stockholders will receive $127 per share in cash.

Following the completion of the acquisition, Integer's common stock has ceased trading and will no longer be listed on the New York Stock Exchange (NYSE).

The acquisition follows a previously announced definitive agreement under which an affiliate of investment funds managed by KKR agreed to acquire all outstanding shares of Integer in an all-cash transaction.

The transaction also received approval from Integer stockholders before its completion.

Headquartered in Plano, Texas, Integer Holdings Corporation is a medical device CDMO serving the cardiovascular, neuromodulation, and cardiac rhythm management markets.

The company works with medical device manufacturers on engineering and manufacturing solutions. Its portfolio includes the Greatbatch Medical and Lake Region Medical brands.

Following the acquisition, Integer joins KKR’s portfolio, adding its capabilities in cardiovascular devices, neuromodulation, and cardiac rhythm management to the investment firm's medical technology portfolio.

The acquisition aims to leverage KKR’s resources to support Integer’s growth strategy, expanding its technological capabilities and strengthening its position in the global medical device industry.

Commenting on the new acquisition, Payman Khales, President and CEO of Integer, said, “Today marks an exciting new chapter for Integer, our associates, customers, and the patients we collectively serve. Together with KKR, we are well positioned to accelerate our growth strategy, further invest in our people, capabilities, and technologies, and continue delivering the expertise and solutions that help our customers bring life-enhancing and life-saving devices to patients around the world.”

The acquisition further expands KKR's presence in the medical technology sector, following its investment in Healthium Medtech, a manufacturer of medical devices and surgical products. In a recent development, KKR-owned Healthium Medtech and Temasek-backed Romsons Group have emerged as key contenders for a proposed acquisition of a 70-80% stake in Delhi-based medical devices manufacturer BL Lifesciences, in a transaction reportedly valuing the fourth-generation, family-owned business at approximately INR 1,800-2,000 crore.

Stay tuned for more such updates on Digital Health News

Follow us

More Articles By This Author


Show All

Welcome back.

Pick up where you left off on Digital Health News.

Sign in to DHN

For existing DHN and DHN Plus members.

or
Continue with Google
New to DHN?